Rna Diagnostics Inc. is an early-stage molecular diagnostics company developing medical diagnostic tools to assist in the management of cancer treatment. The company's first product, RNA Disruption Assay™ (RDA™), is a real time diagnostic test that helps oncologists to rapidly assess the effectiveness of cancer chemotherapy. RDA can determine whether chemotherapy is working effectively in the individual patient early in treatment thereby guiding clinical decision making. Clinical adoption of RDA testing helps patients avoid unnecessary toxicity while saving healthcare systems money.